FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3130191721> ?p ?o ?g. }

• W3130191721 endingPage "1388" @default.
• W3130191721 startingPage "1379" @default.
• W3130191721 abstract "Aim To assess the risk of urinary tract infection (UTI) occurrence associated with sodium-glucose cotransporter-2 (SGLT2) inhibitor use relative to biguanide use in diabetes in a population-based cohort study using a target trial emulation framework. Methods Using a Japanese nationwide administrative claims database, we constructed a cohort of patients aged ≥40 years who were dispensed SGLT2 inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors or biguanides between April 2014 and March 2015. For computational ease, we randomly sampled 100% of SGLT2 inhibitor users, 3% of DPP-4 inhibitor users, and 20% of biguanide users; new antidiabetic drug initiators were analysed. We estimated the intention-to-treat (ITT) hazard ratios (HRs) of UTI with inverse probability of treatment (IPT)-weighted Coxʼs proportional hazards models that ignored subsequent treatment changes. Treatment weights were computed using patient sex, age, medications, medical history and hospitalization history. We also estimated per-protocol (PP) HRs using IPT- and inverse probability of censoring-weighted Coxʼs models that adjusted for nonrandom treatment changes. Results We analysed 11 364 SGLT2 inhibitor initiators, 9035 DPP-4 inhibitor initiators, and 10 359 biguanide initiators. When compared with biguanide initiators, SGLT2 inhibitor initiators had a crude HR of 1.14 (95% confidence interval [CI] 1.05-1.24), an ITT HR of 0.94 (95% CI 0.86-1.03), and a PP HR of 0.90 (95% CI 0.78-1.03); and DPP-4 inhibitor initiators had a crude HR of 1.13 (95% CI 1.04-1.23), an ITT HR of 0.85 (95% CI 0.77-0.94), and a PP HR of 0.83 (95% CI 0.71-0.95). Conclusion Use of SGLT2 inhibitors or DPP-4 inhibitors did not increase the risk of UTI compared with biguanide use. Accounting for treatment changes did not substantially influence the estimated effects." @default.
• W3130191721 created "2021-03-01" @default.
• W3130191721 creator A5005239900 @default.
• W3130191721 creator A5023007444 @default.
• W3130191721 creator A5027529203 @default.
• W3130191721 creator A5058020193 @default.
• W3130191721 creator A5062575717 @default.
• W3130191721 creator A5076707735 @default.
• W3130191721 creator A5088800086 @default.
• W3130191721 date "2021-03-08" @default.
• W3130191721 modified "2023-10-04" @default.
• W3130191721 title "Sodium‐glucose cotransporter‐2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan: Target trial emulation using a nationwide administrative claims database" @default.
• W3130191721 cites W1195241434 @default.
• W3130191721 cites W1998788099 @default.
• W3130191721 cites W2036222770 @default.
• W3130191721 cites W2057112394 @default.
• W3130191721 cites W2062359643 @default.
• W3130191721 cites W2067736115 @default.
• W3130191721 cites W2071066672 @default.
• W3130191721 cites W2072040765 @default.
• W3130191721 cites W2087093311 @default.
• W3130191721 cites W2096057710 @default.
• W3130191721 cites W2100796772 @default.
• W3130191721 cites W2112662877 @default.
• W3130191721 cites W2146327796 @default.
• W3130191721 cites W2150959326 @default.
• W3130191721 cites W2298338128 @default.
• W3130191721 cites W2301210108 @default.
• W3130191721 cites W2332568888 @default.
• W3130191721 cites W2404984931 @default.
• W3130191721 cites W2626411548 @default.
• W3130191721 cites W2773101798 @default.
• W3130191721 cites W2790579026 @default.
• W3130191721 cites W2793906475 @default.
• W3130191721 cites W2794676804 @default.
• W3130191721 cites W2894510523 @default.
• W3130191721 cites W2895533920 @default.
• W3130191721 cites W2900732862 @default.
• W3130191721 cites W2913306188 @default.
• W3130191721 cites W2941544942 @default.
• W3130191721 cites W2954115740 @default.
• W3130191721 cites W2966426030 @default.
• W3130191721 cites W3005269555 @default.
• W3130191721 cites W3005763315 @default.
• W3130191721 cites W4210426420 @default.
• W3130191721 doi "https://doi.org/10.1111/dom.14353" @default.
• W3130191721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33606891" @default.
• W3130191721 hasPublicationYear "2021" @default.
• W3130191721 type Work @default.
• W3130191721 sameAs 3130191721 @default.
• W3130191721 citedByCount "8" @default.
• W3130191721 countsByYear W31301917212021 @default.
• W3130191721 countsByYear W31301917212022 @default.
• W3130191721 countsByYear W31301917212023 @default.
• W3130191721 crossrefType "journal-article" @default.
• W3130191721 hasAuthorship W3130191721A5005239900 @default.
• W3130191721 hasAuthorship W3130191721A5023007444 @default.
• W3130191721 hasAuthorship W3130191721A5027529203 @default.
• W3130191721 hasAuthorship W3130191721A5058020193 @default.
• W3130191721 hasAuthorship W3130191721A5062575717 @default.
• W3130191721 hasAuthorship W3130191721A5076707735 @default.
• W3130191721 hasAuthorship W3130191721A5088800086 @default.
• W3130191721 hasConcept C126322002 @default.
• W3130191721 hasConcept C134018914 @default.
• W3130191721 hasConcept C207103383 @default.
• W3130191721 hasConcept C2777180221 @default.
• W3130191721 hasConcept C2777688063 @default.
• W3130191721 hasConcept C2780031085 @default.
• W3130191721 hasConcept C2780323712 @default.
• W3130191721 hasConcept C2908647359 @default.
• W3130191721 hasConcept C44249647 @default.
• W3130191721 hasConcept C50382708 @default.
• W3130191721 hasConcept C555293320 @default.
• W3130191721 hasConcept C71924100 @default.
• W3130191721 hasConcept C72563966 @default.
• W3130191721 hasConcept C98274493 @default.
• W3130191721 hasConcept C99454951 @default.
• W3130191721 hasConceptScore W3130191721C126322002 @default.
• W3130191721 hasConceptScore W3130191721C134018914 @default.
• W3130191721 hasConceptScore W3130191721C207103383 @default.
• W3130191721 hasConceptScore W3130191721C2777180221 @default.
• W3130191721 hasConceptScore W3130191721C2777688063 @default.
• W3130191721 hasConceptScore W3130191721C2780031085 @default.
• W3130191721 hasConceptScore W3130191721C2780323712 @default.
• W3130191721 hasConceptScore W3130191721C2908647359 @default.
• W3130191721 hasConceptScore W3130191721C44249647 @default.
• W3130191721 hasConceptScore W3130191721C50382708 @default.
• W3130191721 hasConceptScore W3130191721C555293320 @default.
• W3130191721 hasConceptScore W3130191721C71924100 @default.
• W3130191721 hasConceptScore W3130191721C72563966 @default.
• W3130191721 hasConceptScore W3130191721C98274493 @default.
• W3130191721 hasConceptScore W3130191721C99454951 @default.
• W3130191721 hasIssue "6" @default.
• W3130191721 hasLocation W31301917211 @default.
• W3130191721 hasOpenAccess W3130191721 @default.
• W3130191721 hasPrimaryLocation W31301917211 @default.
• W3130191721 hasRelatedWork W1481547275 @default.
• W3130191721 hasRelatedWork W2056185181 @default.

• next